Focal segmental glomerulosclerosis associated with the use of the IL-23 inhibitor guselkumab

We report a case of a 38-year-old man who developed a nephrotic syndrome shortly after the start of guselkumab for the treatment of plaque psoriasis. Renal biopsy showed focal segmental glomerulosclerosis (FSGS). The clinical course of our case is highly suspect for drug-induced FSGS since the nephr...

Descripción completa

Detalles Bibliográficos
Autores principales: Stryckers, Marijke, Van Oevelen, Stefaan, Koshy, Priyanka, Sprangers, Ben, Van Craenenbroeck, Amaryllis H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Exceptional Case
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10539213/
https://www.ncbi.nlm.nih.gov/pubmed/37779841
http://dx.doi.org/10.1093/ckj/sfad161
Descripción
Sumario:We report a case of a 38-year-old man who developed a nephrotic syndrome shortly after the start of guselkumab for the treatment of plaque psoriasis. Renal biopsy showed focal segmental glomerulosclerosis (FSGS). The clinical course of our case is highly suspect for drug-induced FSGS since the nephrotic syndrome resolved after cessation of the drug without relapse (2 years of follow-up). To the best of our knowledge, this is the first case describing FSGS lesions associated with the use of an interleukin-23 inhibitor.

Ejemplares similares